<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> with <z:mpath ids='MPATH_173'>myeloid metaplasia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>The prevalence of this mutation in either "atypical" <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e>) or the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow-derived genomic DNA from 245 patients--119 with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), 101 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 11 with <z:e sem="disease" ids="C1540912" disease_type="Neoplastic Process" abbrv="">hypereosinophilic syndrome</z:e> (HES), 8 with systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (SM), and 6 with <z:hpo ids='HP_0011010'>chronic</z:hpo> neutrophilic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (CNL)--was screened for the JAK2 V617F mutation </plain></SENT>
<SENT sid="3" pm="."><plain>A mutant allele was detected in 11 patients: 3 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> (3%), 5 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (5%), 2 with SM, and 1 with CNL </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and this patient with SM also had associated <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The current observation strengthens the specific association between JAK2 V617F and classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, but also suggests an infrequent occurrence in other myeloid disorders </plain></SENT>
</text></document>